Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: A possible D2 receptor mediated phenomenon?

Psychopharmacology

Volumn 231, Issue 8, 2014, Pages 1649-1659

  Qiao, Jing ^a,c   Gao, Jun ^c   Shu, Qing ^b,c   Zhang, Qinglin ^a   Hu, Gang ^b   Li, Ming ^c  

^a SOUTHWEST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

22 kHz ultrasonic vocalization; Adolescence; Conditioned avoidance response; Motor activity; Phencyclidine; Prepulse inhibition; Quinpirole; Risperidone; Sensitization

Indexed keywords

DOPAMINE 2 RECEPTOR; PHENCYCLIDINE; QUINPIROLE; RISPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; POSTNATAL DEVELOPMENT; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSITIZATION; UPREGULATION; AGING; AGONISTS; ANIMAL; CHEMICALLY INDUCED; CONDITIONING; DOSE RESPONSE; DRUG EFFECTS; FEAR; HYPERKINESIA; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SENSORY GATING; SPRAGUE DAWLEY RAT; ULTRASOUND; VOCALIZATION;

AGING; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; HYPERKINESIS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PREPULSE INHIBITION; QUINPIROLE; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RISPERIDONE; SENSORY GATING; ULTRASONICS; VOCALIZATION, ANIMAL;

EID: 84898600771     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3386-0     Document Type: Article

References (47)

1. Aguilar MA, Rodriguez-Arias M, Mari-Sanmillan MI, Minarro J (1997) Effects of risperidone on conditioned avoidance responding in male mice. Behav Pharmacol 8:669-676
2. Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Archives of disease in childhood Education and practice edition 96:192-196
3. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62
4. Brenhouse HC, Andersen SL (2011) Developmental trajectories during adolescence in males and females: a cross-species understanding of underlying brain changes. Neurosci Biobehav Rev 35:1687-1703
5. Chen J, Wang Z, Li M (2011) Multiple 'hits' during postnatal and early adulthood periods disrupt the normal development of sensorimotor gating ability in rats. J Psychopharmacol 25:379-392
6. Choi YK, Gardner MP, Tarazi FI (2009) Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 19:77-84
7. Choi YK, Moran-Gates T, Gardner MP, Tarazi FI (2010) Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol 20:187-194
8. Correll CU, Kratochvil CJ, March JS (2011) Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72:655-670
9. Culm KE, Hammer RP Jr (2004) Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats. J Pharmacol Exp Ther 308:487-494
10. Gao J, Li M (2013) Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav Brain Res 257:286-294.
11. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84
12. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, de Jong-van den Berg LT (2008) Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59:554-560
13. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631
14. Koller W, Herbster G, Anderson D, Wack R, Gordon J (1987) Quinpirole hydrochloride, a potential anti-parkinsonism drug. Neuropharmacology 26:1031-1036
15. Li M, Fletcher PJ, Kapur S (2007) Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272
16. Li M, He W, Mead A (2009) Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 20:84-98
17. Li M, Sun T, Zhang C, Hu G (2010) Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 212:45-57
18. Luque-Rojas MJ, Galeano P, Suarez J, Araos P, Santin LJ, de Fonseca FR, Calvo EB (2013) Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 16:661-676
19. Mead A, Li M (2010) Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 24:1045-1053
20. Mead A, Li M, Kapur S (2008) Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 90:551-562
21. Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J (2010) Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull 36:607-623
22. Milstein JA, Elnabawi A, Vinish M, Swanson T, Enos JK, Bailey AM, Kolb B, Frost DO (2013) Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function. PLoS One 8:e57308
23. Moran-Gates T, Gan L, Park YS, Zhang K, Baldessarini RJ, Tarazi FI (2006) Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse 59:92-100
24. Moran-Gates T, Grady C, Shik Park Y, Baldessarini RJ, Tarazi FI (2007) Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 17:448-455
25. Nakamura S, Yue JL, Goshima Y, Miyamae T, Ueda H, Misu Y (1994) Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neuroscience letters 170:22-26
26. Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685
27. Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP, Jensen PS (2005) Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 44:548-556
28. Piontkewitz Y, Assaf Y, Weiner I (2009) Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry 66:1038-1046
29. Piontkewitz Y, Arad M, Weiner I (2011) Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 37:1257-1269
30. Piontkewitz Y, Bernstein HG, Dobrowolny H, Bogerts B, Weiner I, Keilhoff G (2012) Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 26:353-363
31. Prosser ES, Pruthi R, Csernansky JG (1989) Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology (Berl) 99:109-116
32. Qiao J, Li H, Li M (2013) Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology 38:513-524
33. Qin R, Chen Y, Li M (2013) Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. Neuropharmacology 75C:356-364
34. Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002-1009
35. Shu Q, Hu G, Li M (2013) Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol, in press doi: 10.1177/0269881113512039
36. Sun T, Hu G, Li M (2009) Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602:334-342
37. Sun T, He W, Hu G, Li M (2010a) Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 95:298-307
38. Sun T, Zhao C, Hu G, Li M (2010b) Iptakalim: a potential antipsychotic drug with novel mechanisms? Eur J Pharmacol 634:68-76
39. Swalve N, Li M (2012) Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol 23:380-391
40. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
41. Swerdlow NR, Braff DL, Geyer MA (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11:185-204
42. Tenk CM, Foley KA, Kavaliers M, Ossenkopp KP (2007) Neonatal immune system activation with lipopolysaccharide enhances behavioural sensitization to the dopamine agonist, quinpirole, in adult female but not male rats. Brain, behavior, and immunity 21:935-945
43. Vinish M, Elnabawi A, Milstein JA, Burke JS, Kallevang JK, Turek KC, Lansink CS, Merchenthaler I, Bailey AM, Kolb B, Cheer JF, Frost DO (2013) Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function. Int J Neuropsychopharmacol 16:1599-1609
44. Vorhees CV, Johnson HL, Burns LN, Williams MT (2009) Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze. Neurotoxicol Teratol 31:1-10
45. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001) Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-641
46. Zhang C, Li M (2012) Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol 23:66-79
47. Zhang C, Fang Y, Li M (2011) Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence. Pharmacol Biochem Behav 98:155-160